Insight journal, Insight journal - Company

Sun Pharmaceutical: Fast becoming the branded generic company of choice

Posted on 30 June 2014

Tags: , ,

Sun Pharmaceutical is a global specialty pharmaceutical company serving over 40 different markets with its brands and branded generics.

Based in India but operating with the help of its US subsidiary Caraco, Sun Pharmaceutical offers over 1,000 marketed products that focus upon neurology, cardiology, ophthalmology, psychiatry, gastroenterology and orthopaedics.

From its humble beginnings in Gujarat, India in 1983 Sun Pharmaceuticals has grown to become India’s 5th largest pharmaceutical company and is rapidly becoming the branded generic company of choice. Looking back over its 30 year history the company first went public in 1994 and this was just shortly after establishing its first research centre in the early nineties. The company then went onto acquire a number of assets and companies including ICN in Hungary from Valeant Pharmaceuticals,  Chattern Chemicals in 2008 and more recently in 2012 Dusa Pharma and the generic business of URL Pharma.

The company’s many acquisitions and product success has helped it build over 720 manufacturing facilities and employ over 14,000 professionals.  Sun Pharmaceutical is building by the day.

Partnering is the lifeblood

The act of partnering and acquiring is essential to Sun Pharmaceutical as it helps it nurture and adds to its product portfolio. The company attracts potential partners by demonstrating that it has a field force of 600 in 41 countries and has over 2,400 stockists marketing 25 – 30 new products a year. Sun Pharmaceutical is looking to both sides of licensing to support and complement its growth:

In licensing

Sun Pharmaceutical is looking for products at the late stage clinical or marketed stage that focus upon its key therapeutic areas, which are:

We look at partnering and collaborating as an important strategic approach that will complement our growth in India and international markets. Our constant need is to add to our speciality product portfolio for prescription leadership in India. We also seek to strengthen our presence, with a complete basket of speciality products, in Russia and CIS countries, China and South East Asia, Africa, Brazil and Mexico.

  • CNS disorders
  • Cardiology
  • Diabetes and Metabolic disorders
  • Gastroenterology
  • Ophthalmology
  • Oncology
  • Pain
  • Allergy, Asthma and Inflammation
  • Gynecologicals

Sun Pharmaceutical is also interested in licensing biosimilar products and recombinant/humanized monoclonal antibody based products in the above therapy areas.

Not content with just bringing in products, Sun Pharmaceutical also seeks to out license its range of dosage forms for oral, injectable, topical and transdermal routes which have been perfected by the company’s expertise in developing complex generic products which are bioequivalent, sustained release oral dosage forms of long acting injectable depot formulations.

Out-licensing opportunities are also available for the company’s specialty generics, super generics and bulk drugs for global markets in the following indications:

  • CVS
  • CNS
  • Pain
  • Cancer
  • Gynecologicals
  • Allergy, Asthma other respiratory diseases

Partnering outreach

Sun Pharmaceutical is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.

Other events with Sun Pharmaceutical’s presence include but are not limited to:

  • BIO International Convention and Business Forum
  • BioEurope / BioEurope Spring

For a full list of forthcoming partnering events where you could meet with Sun Pharmaceutical in person visit Current Partnering’s Event calendar.     

Contacting Sun Pharmaceutical for partnering

Sun Pharmaceutical can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:    

Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.

See Current Partnering’s event calendar for details of forthcoming events.    

Direct contact: there are several sources of direct contact with Sun Pharmaceutical’s business development team

-        Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.

-        Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Sun Pharmaceutical’s website has details for contacting Sun Pharmaceutical.

-        LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.

Many of Sun Pharmaceuticalbusiness development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Sun Pharmaceutical Linkedin Page.  

Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the contacts page on Sun Pharmaceutical website for potential partnering opportunities and general contact names.   

Raveena Bhambra    


Sun Pharmaceutical partnering at Current Agreements                                          

View all partnering deals for Sun Pharmaceutical: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 

Full details on each deal can be found at Current Agreements (subscription required)

Or purchase report: Partnering Agreements with Sun Pharmaceutical 2009-2014


Summary profile data for Sun Pharmaceutical

Partnering activity for Sun Pharmaceutical

M&A activity for Sun Pharmaceutical


Available reports from Current Partnering 

Report: Partnering Agreements with Sun Pharmaceutical 2009-2014 

Report: Top 50 Big Pharma Partnering and M&A Deal Trends     


Available resources for deal coverage for Sun Pharmaceutical 

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more 

Read: more on Sun Pharmaceutical company profile, recent partnering, M&A and financing news and articles



View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply